[Pharmaceutical device of IFN].
Recently, new types of interferon (IFN) agents, such as pegylated IFN (PEG-IFN) and consensus IFN, have been developed for strong therapeutic effect and used in clinical stage. PEG-IFN, which is the conjugation of IFN and polyethylene glycol, was designed to long circulate in blood and decrease antibody production. Consensus IFN was designed to combine amino acid frequently appeared in IFN-alpha subtypes. Although they improved IFN therapy, it is also important to pay attention to side effect. Characteristics of new type IFN agents were summarized focused on their pharmaceutical designs.
Higuchi
Yuriko
Y
Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto University.
Hashida
Mitsuru
M
D000595:Amino Acid Sequence; D000998:Antiviral Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D016503:Drug Delivery Systems; D015195:Drug Design; D015316:Genetic Therapy; D005822:Genetic Vectors; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007372:Interferons / Q000008:administration & dosage / Q000493:pharmacokinetics; D010316:Particle Size; D011092:Polyethylene Glycols; D011994:Recombinant Proteins
D000998:Antiviral Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C050739:interferon alfacon-1; D007372:Interferons; C100416:peginterferon alfa-2a